Skip to main content

  • Access Route and Clinical Outcomes After Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome Undergoing Invasive Treatment Strategy

    • Posted: 07/14/2022
    • Author:

      Rayyan Hemetsberger, Gert Richardt, Shqipdona Lahu, Christian Valina, Maurizio Menichelli, Mohammad Abdelghani, Jochen Wöhrle, Ralph Toelg, Bernhard Witzenbichler, Nader Mankerious, Christoph Liebetrau, Isabell Bernlochner, Christian W. Hamm, Abdelhakim Allali, Michael Joner, Massimiliano Fusaro, Erion Xhepa, Alexander Hapfelmeier, Sebastian Kufner, Hendrik B. Sager, Stefanie Schüpke, Karl-Ludwig Laugwitz, Heribert Schunkert, Franz-Josef Neumann, Adnan Kastrati and Salvatore Cassese

    • 2022CRM

    Abstract

    Background

    Whether the access site influences the comparative efficacy and safety of ticagrelor and prasugrel in patients with acute coronary syndrome (ACS) undergoing invasive treatment strategy remains unstudied.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details